Patient pretreatment characteristics
| Pretreatment characteristics . | Value . |
|---|---|
| Age, y | 71 (66-85) |
| Hemoglobin, g/dL | 12.4 (8.9-16.4) |
| Platelets, ×109/L | 155 (63-464) |
| White cell count, ×109/L | 84.0 (4.9-245) |
| Lymphocytes, ×109/L | 76.4 (2.5-227) |
| Absolute neutrophils, ×109/L | 3.9 (0-22.6) |
| β2-microglobulin, mg/L | 4.3 (2-10.2) |
| Rai stage | |
| 0 | 3 (5) |
| I or II | 39 (65) |
| III | 7 (12) |
| IV | 11 (18) |
| Charlson Comorbidity Score* | |
| 0 | 6 (10) |
| 1 or 2 | 34 (57) |
| 3 or 4 | 19 (32) |
| ≥ 5 | 1 (2) |
| Sex | |
| Female | 26 (43) |
| Male | 34 (57) |
| CD38 flow | |
| < 30% | 29 (48) |
| > 30% | 30 (50) |
| Zap-70 flow (ND = 29, 48%) | |
| < 20% | 14 (24) |
| > 20% | 17 (28) |
| IGHV mutational status | |
| Mutated | 22 (37) |
| Unmutated | 33 (55) |
| FISH, bone marrow | |
| 13q deletion | 15 (25) |
| Negative | 12 (20) |
| Trisomy 12 | 13 (22) |
| 11q deletion | 14 (23) |
| 17p deletion | 6 (10) |
| Pretreatment characteristics . | Value . |
|---|---|
| Age, y | 71 (66-85) |
| Hemoglobin, g/dL | 12.4 (8.9-16.4) |
| Platelets, ×109/L | 155 (63-464) |
| White cell count, ×109/L | 84.0 (4.9-245) |
| Lymphocytes, ×109/L | 76.4 (2.5-227) |
| Absolute neutrophils, ×109/L | 3.9 (0-22.6) |
| β2-microglobulin, mg/L | 4.3 (2-10.2) |
| Rai stage | |
| 0 | 3 (5) |
| I or II | 39 (65) |
| III | 7 (12) |
| IV | 11 (18) |
| Charlson Comorbidity Score* | |
| 0 | 6 (10) |
| 1 or 2 | 34 (57) |
| 3 or 4 | 19 (32) |
| ≥ 5 | 1 (2) |
| Sex | |
| Female | 26 (43) |
| Male | 34 (57) |
| CD38 flow | |
| < 30% | 29 (48) |
| > 30% | 30 (50) |
| Zap-70 flow (ND = 29, 48%) | |
| < 20% | 14 (24) |
| > 20% | 17 (28) |
| IGHV mutational status | |
| Mutated | 22 (37) |
| Unmutated | 33 (55) |
| FISH, bone marrow | |
| 13q deletion | 15 (25) |
| Negative | 12 (20) |
| Trisomy 12 | 13 (22) |
| 11q deletion | 14 (23) |
| 17p deletion | 6 (10) |
Values are median (range) or n (%).
CD38 flow indicates CD38 expression by flow cytometry on CD19+ lymphocytes in bone marrow aspirate; Zap-70 flow, Zap-70 expression by flow cytometry on peripheral blood B-lymphocytes; IGHV, immunoglobulin variable heavy chain; and ND, not done.
Charlson et al.20